Cardiac lineage determination and nuclear architecture
心脏谱系测定和核结构
基本信息
- 批准号:10449605
- 负责人:
- 金额:$ 3.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAmino AcidsArchitectureCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular systemCell NucleusCell divisionCellsCharacteristicsChromatinCodeComplexDNADNA biosynthesisDataDaughterEpigenetic ProcessEpitopesExcisionFoundationsGene ExpressionGene Expression RegulationGenesGenomeGlucoseGoalsHeart DiseasesHistonesLaminsMalignant NeoplasmsMediatingMetabolicMetabolismMitosisModelingMyocardial InfarctionNuclearNuclear EnvelopeNuclear Inner MembranePatternPhosphorylationPredispositionPublishingPyruvate KinaseRegulationScientistSignal TransductionTailTestingaurora B kinasecancer cellcardiac regenerationdaughter cellepigenetic memoryfatty acid metabolismgenome-widegenomic locusinnovationnovelprogramsregenerative approachregenerative therapystem cellstransdifferentiation
项目摘要
This R35 application proposes a conceptual framework in which a body of work produced by the PI over the past
20 years is utilized as the foundation for launching innovative studies that seek to incorporate cutting edge
understanding of nuclear architecture (how chromatin is organized in three dimensions in the nucleus) to produce
a novel paradigm of lineage determination and cell fate identity. The goal is to better understand how broad
gene expression programs that characterize cell identity are regulated in order to inform regenerative
approaches to cardiovascular disease. Preliminary data suggest that regions of the genome that are localized
to the nuclear periphery (called “lamin associated domains” or LADs) are silenced by specific histone marks,
including H3K9me2, and that these regions are released from the periphery upon lineage determination in order
to allow for simultaneous activation of entire gene programs. Data suggests that the H3K9me2 mark
characteristic of LADs is “remembered” through mitosis providing a mechanism for epigenetic memory of lineage
identity. The proposed model suggests that epigenetic marks such as H3K9me2 that define LADs are
recognized by “LAD-tethers” that mediate spatial localization, and that these histone epitopes can be “shielded”
by phosphorylation of adjacent amino acid residues of the histone tails (including phosphorylation of H3S10 and
H3T11). We propose to test that during mitosis, aurora B kinase which phosphorylates H3S10, acts to un-tether
LADs by shielding the H3K9me2 epitope, allowing for the release of LADs, subsequent breakdown of the nuclear
membrane and DNA replication, followed by removal of S10 phosphorylation and re-establishment of LADs as
the daughter nuclear membranes form around the exposed histone mark. Thus, if the genome-wide pattern of
LADs in a given cell defines its identity by representing a “code” of silenced alternative lineage programs, then
cellular identity can be remembered through mitosis and efficiently re-established in daughter cells. Implications
for reprogramming, trans-differentiation, asymmetric cell division, and stability of lineage identity (and thus
cancer susceptibility) will be explored. Signal transduction cascades that regulate dramatic changes in cellular
metabolism and function (such as the switch between glucose and fatty acid metabolism characteristic of
developing and ailing cardiac myocytes and of cancer cells) may impact nuclear architecture and LAD dynamics
by converging on phosphorylation of histone residues including H3T11. This notion is supported by published
data indicating that a nuclear form of pyruvate kinase that is implicated in metabolic shifts can phosphorylate
H3T11 and can interact with Hdac3 which we have shown is a LAD tether, resulting in epigenetic changes and
activation of specific gene loci. Thus, this proposal provides the opportunity to provide experimental support for
a model of gene regulation and cellular identity that incorporates three dimensional regulation of chromatin
packaging within the nucleus extending our understanding of cellular identity and providing a novel mechanism
to understand the way in which entire gene programs are coordinately regulated.
该 R35 应用程序提出了一个概念框架,其中包含 PI 过去所做的工作主体
20年被用作开展创新研究的基础,旨在融合尖端技术
了解核结构(染色质如何在细胞核的三个维度上组织)以产生
谱系决定和细胞命运身份的新范式的目标是更好地理解其广泛性。
表征细胞身份的基因表达程序受到调节,以告知再生
初步数据表明基因组区域是局部的。
核外围(称为“核纤层蛋白相关结构域”或 LAD)被特定的组蛋白标记沉默,
包括H3K9me2,并且这些区域在谱系确定后从外围释放,以便
允许同时激活整个基因程序 数据表明 H3K9me2 标记。
LAD 的特征通过有丝分裂被“记住”,为谱系的表观遗传记忆提供了机制
所提出的模型表明,定义 LAD 的表观遗传标记(例如 H3K9me2)是相同的。
被介导空间定位的“LAD-tethers”识别,并且这些组蛋白表位可以被“屏蔽”
通过组蛋白尾部相邻氨基酸残基的磷酸化(包括 H3S10 和 H3S10 的磷酸化)
H3T11)。我们建议测试在有丝分裂过程中,磷酸化 H3S10 的极光 B 激酶的作用,以解除束缚。
LADs 通过屏蔽 H3K9me2 表位,允许释放 LADs,随后破坏核
膜和 DNA 复制,然后去除 S10 磷酸化并重建 LAD,如下所示
子核膜在暴露的组蛋白标记周围形成,因此,如果全基因组模式。
给定细胞中的 LAD 通过代表沉默的替代谱系程序的“代码”来定义其身份,然后
细胞身份可以通过有丝分裂被记住并在子细胞中有效地重建。
用于重编程、转分化、不对称细胞分裂和谱系身份的稳定性(因此
癌症易感性)将被探索调节细胞的巨大变化的信号转导级联。
代谢和功能(例如葡萄糖和脂肪酸代谢特征之间的转换)
发育中和患病的心肌细胞和癌细胞)可能会影响核结构和 LAD 动力学
通过聚合包括 H3T11 在内的组蛋白残基的磷酸化,这一观点得到了已发表的文章的支持。
数据表明与代谢变化有关的丙酮酸激酶的核形式可以磷酸化
H3T11 可以与 Hdac3 相互作用,我们已经证明 Hdac3 是 LAD 系链,导致表观遗传变化和
因此,该提案提供了为以下方面提供实验支持的机会。
整合染色质三维调控的基因调控和细胞身份模型
细胞核内的包装扩展了我们对细胞身份的理解并提供了一种新的机制
了解整个基因程序的协调调节方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan A. Epstein其他文献
Hypertrophic cardiomyopathy--beyond the sarcomere.
肥厚型心肌病——超出肌节。
- DOI:
- 发表时间:
1998 - 期刊:
- 影响因子:158.5
- 作者:
M. J. Sutton;Jonathan A. Epstein - 通讯作者:
Jonathan A. Epstein
Pax3 and vertebrate development.
- DOI:
10.1385/1-59259-066-7:459 - 发表时间:
2000 - 期刊:
- 影响因子:0
- 作者:
Jonathan A. Epstein - 通讯作者:
Jonathan A. Epstein
Jonathan A. Epstein的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan A. Epstein', 18)}}的其他基金
Cardiac lineage determination and nuclear architecture
心脏谱系测定和核结构
- 批准号:
10555314 - 财政年份:2018
- 资助金额:
$ 3.57万 - 项目类别:
Cardiac lineage determination and nuclear architecture
心脏谱系测定和核结构
- 批准号:
10532554 - 财政年份:2018
- 资助金额:
$ 3.57万 - 项目类别:
Cardiac lineage determination and nuclear architecture
心脏谱系测定和核结构
- 批准号:
10092212 - 财政年份:2018
- 资助金额:
$ 3.57万 - 项目类别:
Cardiac lineage determination and nuclear architecture
心脏谱系测定和核结构
- 批准号:
10329887 - 财政年份:2018
- 资助金额:
$ 3.57万 - 项目类别:
The role of nuclear architecture in cardiac development
核结构在心脏发育中的作用
- 批准号:
9258488 - 财政年份:2016
- 资助金额:
$ 3.57万 - 项目类别:
Semaphorin3d and anomalous pulmonary venous return
Semaphorin3d 和异常肺静脉回流
- 批准号:
8896860 - 财政年份:2013
- 资助金额:
$ 3.57万 - 项目类别:
Semaphorin3d and anomalous pulmonary venous return
Semaphorin3d 和异常肺静脉回流
- 批准号:
9108432 - 财政年份:2013
- 资助金额:
$ 3.57万 - 项目类别:
Semaphorin3d and anomalous pulmonary venous return
Semaphorin3d 和异常肺静脉回流
- 批准号:
8705007 - 财政年份:2013
- 资助金额:
$ 3.57万 - 项目类别:
Semaphorin3d and anomalous pulmonary venous return
Semaphorin3d 和异常肺静脉回流
- 批准号:
8583466 - 财政年份:2013
- 资助金额:
$ 3.57万 - 项目类别:
Notch signaling in cardiovascular morphogenesis
心血管形态发生中的Notch信号传导
- 批准号:
8011429 - 财政年份:2010
- 资助金额:
$ 3.57万 - 项目类别:
相似国自然基金
中性氨基酸转运体SNAT2在血管稳态和重构中的作用及机制
- 批准号:82370423
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
催化不对称自由基反应合成手性α-氨基酸衍生物
- 批准号:22371216
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
BRD9通过表观重塑促进支链氨基酸代谢介导TP53突变型胰腺癌化疗耐药的机制研究
- 批准号:82360519
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
氨基酸转运体SLC7A5诱导食管癌免疫治疗获得性耐药的机制研究
- 批准号:82373410
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
(光)电催化硝酸根和有机酸C-N偶联合成氨基酸
- 批准号:22372162
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.
MetabolGut:一个快速检测平台,使用干细胞驱动的人体吸收性肠上皮细胞来评估药物对脂质处理途径和乳糜微粒相关药物分布的影响。
- 批准号:
10766493 - 财政年份:2023
- 资助金额:
$ 3.57万 - 项目类别:
4D controllable extracellular matrix properties to guide iPSC-derived intestinal organoid fate and form
4D 可控细胞外基质特性指导 iPSC 衍生的肠道类器官的命运和形成
- 批准号:
10644759 - 财政年份:2023
- 资助金额:
$ 3.57万 - 项目类别:
UBIQUIBODY PLATFORM FOR TARGETED DEGRADATION OF ONCOGENIC FUSION PROTEINS
用于靶向降解致癌融合蛋白的 Ubiquibody 平台
- 批准号:
10806354 - 财政年份:2023
- 资助金额:
$ 3.57万 - 项目类别:
Function, composition, and mechanism of RNA splicing factories in cardiomyopathy
RNA剪接工厂在心肌病中的功能、组成和机制
- 批准号:
10583011 - 财政年份:2022
- 资助金额:
$ 3.57万 - 项目类别: